Pfizer Remembers One other Blood Strain Treatment

April 25, 2022

The pharmaceutical firm Pfizer has voluntary recalled a blood strain treatment for the second time in a month.

Pfizer is recalling 5 numerous blood strain medication Accupril due to elevated ranges of a nitrosamine, Nnitroso-quinapril, the corporate stated in a news release posted Friday on the FDA web site.

Nitrosamines are present in water and meals, together with grilled meats and dairy merchandise, however impurities might improve an individual’s most cancers threat over lengthy intervals of time, Pfizer stated.

Accupril is used to decrease blood strain and handle coronary heart failure. Pfizer stated it has not acquired any reviews of hostile reactions by folks taking the drug.

“Pfizer believes the profit/threat profile of the merchandise stays constructive primarily based on presently obtainable knowledge. Though long-term ingestion of Nnitroso-quinapril could also be related to a possible elevated most cancers threat in people, there isn’t any instant threat to sufferers taking this treatment,” the corporate stated.

The Accupril tables are offered in 10-, 20- and 40-mg doses. The affected lot numbers are DR9639, DX8682, DG1188, DX6031, and CK6260.

Sufferers taking the product ought to discuss to their physician. Sufferers with the affected product ought to name 888-345-0481.

Pfizer recalled one other blood strain treatment on March 22.

The affected merchandise in that recall are quinapril HCl/hydrochlorothiazide (Accuretic) tablets that Pfizer distributes, and two approved generics, quinapril plus hydrochlorothiazide and quinapril HCl/hydrochlorothiazide, distributed by Greenstone. The recall is over greater than accepted ranges of N-nitroso-quinapril, a compound generally known as a nitrosamine.


Leave a Reply